[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperlipidaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperlipidaemia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,57,93,124,153,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100651536","phase-4-icosapent-ethyl-for-high-risk-coronary-plaques-assessed-by-18f-naf-petct-100651536",false,"NCT07762755","Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET\u002FCT","A Randomized Controlled Trial Evaluating the Effect of Icosapent Ethyl on High-Risk Coronary Plaques Using 18F-Sodium Fluoride PET\u002FCT","IPE-NaF","Inclusion Criteria:\n\n* Male or female participants aged 18 to 75 years.\n* Ability to understand the study and provide written informed consent before enrollment.\n* Receiving a stable lipid-lowering regimen before enrollment, with the type and dose of statin therapy remaining unchanged for at least 4 weeks.\n* Fasting triglyceride level below 5.6 mmol\u002FL.\n* Presence of at least one of the following high-risk plaque features on coronary computed tomography angiography (CCTA):Pericoronary fat attenuation index greater than -70.1 Hounsfield units;\n* Low-attenuation plaque below 30 Hounsfield units;\n* Positive remodeling index greater than 1.1;\n* Spotty calcification;\n* or Napkin-ring sign, defined as a low-attenuation plaque core surrounded by a rim of higher attenuation.\n\nExclusion Criteria:\n\n* Current participation in another investigational drug, device, or procedure study, or receipt of an investigational drug or device within 4 weeks before enrollment.\n* Treatment with icosapent ethyl within 12 months before enrollment.\n* Known intolerance or hypersensitivity to icosapent ethyl or fish oil.\n* A previous diagnosis of homozygous familial hypercholesterolemia or hyperlipidemia requiring hemodialysis.\n* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, or stroke within 3 months before enrollment;\n* Planned cardiac surgery, percutaneous coronary intervention, or carotid artery stenting, or planned major noncardiac surgery during the study.\n* A known contraindication or limitation to PET\u002FCT, including exceeding scanner weight limits or having a device, carotid or aortic stent, or vascular graft that may cause imaging artifacts.\n* Autoimmune disease, vasculitis, or active inflammatory disease.\n* Serious infection within 1 month before enrollment or a current infection requiring intravenous antibiotic treatment.\n* Use within 6 weeks before enrollment or current use of medications that may significantly affect plaque inflammation, including oral, rectal, or injectable corticosteroids or immunosuppressive agents, such as cyclosporine, methotrexate, tacrolimus, azathioprine, antithymocyte globulin, sirolimus, anti-tumor necrosis factor agents such as infliximab, anti-interleukin-6 therapy such as tocilizumab, or anti-interleukin-1 therapy.\n* Use within 6 weeks before enrollment or current use of aspirin at a dose greater than 325 mg\u002Fday or nonsteroidal anti-inflammatory drugs at a dose greater than 1,000 mg\u002Fday.\n* Treatment within 12 months before enrollment with a cholesteryl ester transfer protein inhibitor, including anacetrapib, dalcetrapib, or evacetrapib, or with mipomersen or lomitapide.\n* Known clinically significant systemic disease, including hepatic, renal, hematologic, or malignant disease, or any other clinically significant comorbidity that may interfere with study participation or study assessments.\n* History of malignancy within the previous 5 years, except nonmelanoma skin cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, or stage I prostate cancer.\n* Inability or anticipated inability to complete all protocol-required visits or procedures, or any condition that may make the participant unreliable for study participation, including alcohol or other substance abuse within the previous year or a psychiatric disorder.\n* Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during study treatment or within 15 weeks after the last dose of study treatment.","ALL","18 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This randomized controlled study will evaluate whether icosapent ethyl (IPE) can improve and stabilize high-risk coronary plaques in patients receiving stable low-density lipoprotein cholesterol (LDL-C)-lowering therapy. Potential participants will have coronary plaques identified by coronary computed tomography angiography (CCTA), with 30% to 70% narrowing in at least one major coronary artery and at least one high-risk plaque feature.\n\nAfter baseline imaging with fluorine-18 sodium fluoride positron emission tomography\u002Fcomputed tomography (18F-NaF PET\u002FCT), eligible participants will be randomly assigned in a 1:1 ratio to receive either IPE 2 g twice daily plus standard LDL-C-lowering therapy or standard LDL-C-lowering therapy alone for 12 months. At the end of treatment, participants will undergo repeat CCTA and 18F-NaF PET\u002FCT. Blood biomarkers and major adverse cardiovascular events will also be assessed during follow-up.",[28,29,30,31],"Coronary Artery Disease","Hyperlipidaemia","Hypertriglyceridaemia","Coronary Atherosclerosis",[33,34,35,36,31,37,38,39,40,41,42,43],"Icosapent Ethyl","IPE","High-Risk Coronary Plaque","Coronary Plaque Stabilization","Intermediate Coronary Stenosis","18F-Sodium Fluoride PET\u002FCT","18F-NaF PET\u002FCT","Coronary Computed Tomography Angiography","CCTA","Coronary Microcalcification","Pericoronary Fat Attenuation Index","NOT_YET_RECRUITING","2026-08-11",{"date":47,"type":48},"2026-08-13","ACTUAL",{"date":50,"type":22},"2026-08-01",{"date":52,"type":22},"2029-12-31",{"name":54,"class":55},"China National Center for Cardiovascular Diseases","OTHER_GOV",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":71,"conditions":72,"keywords":79,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100643950","early-phase-1-team-based-shared-decision-making-program-in-cardiovascular-kidney-metabolic-health-100643950","NCT07662616","Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health","Feasibility and Efficacy Pilot of a Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health, Medication Adherence, and Cardiovascular Health","SDM in CKM","Inclusion Criteria:\n\n* Are adults aged 30 to 79 years (to use PREVENT equations to calculate 10- and 30-year risk estimates for total CVD),\n* Are in stage 2 CKM: the presence of metabolic risk factors (hypertension \\[stages 1 and 2\\], hypertriglyceridemia \\[≥135 mg\u002FdL\\], diabetes, Metabolic Equivalents (MetS)\\*) and\u002For Chronic Kidney Disease (CKD) \\[moderate- to high-risk CKD which are stages 1-3 CKD\\]), and\n* Receive primary care at Johns Hopkins Community Physicians (JHCP).\n* Access to smart phone or tablet to use app.\n\nExclusion Criteria:\n\n* Have diagnosis of CVD,\n* Stage 4-5 CKD, kidney failure, or on dialysis\n* Have a serious medical condition such as cancer;\n* On or planning to start Glucagon-like peptide-1 (GLP-1) receptor agonists in next 6 months;\n* Have cognitive impairment;\n* Are currently involved in other programs on improving LE8; or\n* Unwillingness to provide informed consent\n* Unable to speak, read, or communicate in English.","30 Years","79 Years",{"count":68,"type":22},94,[70],"EARLY_PHASE1","The investigators are proposing a new team-based shared decision-making (SDM) program. The goal of this study is to see whether this program is practical and whether it may help adults with cardiometabolic risk factors and cardiovascular-kidney-metabolic syndrome. The investigators will enroll adults from a primary care clinic in Maryland. People in the intervention group will take part in the 6-month program in addition to usual care. People in the control group will receive usual care only.",[73,74,29,75,76,77,78],"Hypertension (HTN)","Diabetes (DM)","Kidney Disease","Obesity","Cardiovascular-kidney-metabolic (CKM)","Overweight",[80,81,82,83],"shared decision-making","Cardiovascular-kidney-metabolic","Behavioral counseling","Team-based care",{"date":85,"type":48},"2026-08-12",{"date":87,"type":22},"2026-09-10",{"date":89,"type":22},"2028-06-30",{"name":91,"class":92},"Johns Hopkins University","OTHER",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":56},"100619071","implementation-and-evaluation-of-a-pharmacist-led-diabetes-care-pathway-in-alberta-community-pharmacies-100619071","NCT07339852","Implementation and Evaluation of a Pharmacist-led Diabetes Care Pathway in Alberta Community Pharmacies","Implementation and Evaluation of a Pharmacist-led Diabetes Care Pathway in Alberta Community Pharmacies.","D-PATH","Inclusion Criteria:\n\n1. Individuals aged 18 years or older.\n2. Individuals with type 2 diabetes.\n3. Individuals with type 2 diabetes not reaching HbA1c target of under 7.0%\n\nExclusion Criteria:\n\n1. Individuals with type 1 diabetes, gestational diabetes, or other forms of diabetes that are not type 2 diabetes.\n2. Pregnant individuals.\n3. Individuals at their HbA1c target (HbA1c under 7.0%) or those with a limited life expectancy, frailty, or lack hypoglycemic awareness (i.e., those with an A1c target above 7.0%) .\n4. Individuals unable to provide consent or who are unwilling to attend follow-up visits.",{"count":102,"type":22},600,[104],"NA","As of 2024, nine percent of Albertans are living with Type 2 diabetes, which increases their risk for cardiovascular disease, stroke, blindness, and kidney failure. Unfortunately, less than half of patients have controlled Type 2 diabetes. We are well aware of the factors which lead to worsening diabetes, but need to give people more support to help them manage their diabetes. Pharmacists are respected health care professionals who are often easier to see that doctors and can help people with diabetes to stay as healthy as possible.\n\nThis research project aims to see whether a pharmacist service can help improve diabetes management in people with type 2 diabetes compared to usual care from their family physician or nurse practitionner. The potential impact of this project is to empower people with type 2 diabetes to understand their condition, it's management, and to achieve target blood sugar levels, which will ultimately reduce the risk of diabetes-related complications.",[107,108,29],"Diabetes Mellitus","Hypertension",[110,111,112,113],"diabetes","pharmacist","pathway","shared decision making","RECRUITING","2026-01-05",{"date":117,"type":48},"2026-01-14",{"date":119,"type":48},"2025-10-13",{"date":121,"type":22},"2026-10-01",{"name":123,"class":92},"University of Alberta",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":130,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100595831","developing-an-ai-pharmacy-chatbot-for-the-population-of-hong-kong-100595831","NCT07037563","Developing an AI Pharmacy Chatbot for the Population of Hong Kong","Inclusion Criteria:\n\n* Patients aged 18 years or older diagnosed with either hyperglycaemia, hypertension, or hyperlipidaemia, and currently receiving medication prescribed by the Hospital Authority in Hong Kong.\n* Caregivers aged 18 years or older for patients described above.\n\nExclusion Criteria:\n\n* There is no exclusion criterion, but they should meet the inclusion criteria above.",true,{"count":132,"type":22},280,[104],"The primary objective of this study is to is to develop a conversational AI service (chatbot) in Hong Kong to assist patients and caregivers with inquires related to Hospital Authority (HA)-prescribed medications, and to evaluate its effectiveness in answering medication-related questions. The main questions it aims to answer are:\n\n1. How satisfied are the patients and caregivers with this pharmacy chatbot?\n2. How will the pharmacy chatbot impact eligible patients or caregivers on their (or the patient they are caring for) medication adherence, knowledge, and the consultation time with HA pharmacists?\n\nThere will be an intervention group and a control group:\n\n1. The intervention group will be invited to use the AI Pharmacy Chatbot online for 7 days through WhatsApp, a commonly used social media platform in Hong Kong. They can inquire about their medications prescribed under HA and get instant, validated answers from the chatbot.\n2. The control group will not use the chatbot during the intervention period.\n\nTo evaluate the chatbot's usability, researchers will measure patient satisfaction through usability questionnaires issued to the intervention group after their intervention period. Differences in medication adherence, medication knowledge, and HA pharmacist consultation time will also be measured between the intervention and control groups after the intervention period, to determine the chatbot's impact.",[136,108,29,137],"Hyperglycaemia","Artificial Intelligence (AI)",[139,140,141,142],"Chatbot","Intelligent Conversational Agent","Artificial Intelligence","Implementation Science","2025-06-17",{"date":145,"type":48},"2025-06-25",{"date":147,"type":22},"2025-06",{"date":149,"type":22},"2026-10-31",{"name":151,"class":92},"The University of Hong Kong",2,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":172,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":187,"leadSponsor":189,"locationsCount":56},"100595747","supporting-patients-starting-new-medicines-evaluating-the-mycare-start-service-in-switzerland-100595747","NCT07036471","Supporting Patients Starting New Medicines: Evaluating the myCare Start Service in Switzerland","Evaluation of the myCare Start Service to Support Patients Starting a New Medicine in Switzerland: A Hybrid Type II Effectiveness-implementation Study","myCare Start-I","Patients\n\nInclusion Criteria:\n\n* Must have mandatory basic health insurance in Switzerland\n* Must have been newly prescribed one or more new long-term medications in accordance with the following chronic conditions: cadisovascular diseases (incl. hyertension and thromboprophylaxis), diabetes, hyperlipidemia, depression, respiratory illness (asthma and COPD)\n* Must be able to self-manage treatment (i.e. they live at home without any support to manage their medication, exception: patient uses a pill dispenser and fills it in by him-\u002Fherself)\n* Must be able to understand language spoken by pharmacy staff and can read and understand study documents (French, German, English)\n* Must understand and are willing to consent to the myCare Start-I study (including the agreement on self-reported questionnaires and collection of health care data via their health insurance company)\n* in the intervention arm, patients must receive the myCare Start service\n\nFor this study, a new medication is a medication that has not been previously dispensed to the patient. This includes one or more new medications for a new diagnosis and or new medications for pre-existing diagnosis of a long-term condition. Included in this working definition:\n\n* The new medication is indicated for one of the five long-term diseases listed above\n* Patient has never had this active ingredient dispensed before (patient still considered eligible if they have received a small initial sample pack from their physician) or restarts an active ingredient after a period of interruption of at least 12 months (time period to be reported by the patient). Please note that for patients, that have already started a sample pack of medication the myCare Start Consultation One can start upon first dispensation at the pharmacy, there is no need to wait 7-14 days.\n* The new active ingredient can be part of a combo preparation (e.g. a diuretic added to an ACE inhibitor into the same preparation)\n* Patient has had no change in active ingredient but has an important change in treatment administration, such as:\n\n  * Change of galenic form (e.g. two different types of inhalators for asthma\u002FCOPD)\n  * Intensification of dosage regiment (e.g. twice a day instead of once a day)\n* The following change is not considered as medication initiation:\n\n  * New dosage of already known active ingredient (e.g. dose escalation of antidepressants)\n  * Simplification of administration mode (e.g. metformin 1000 mg 1-0-0 instead of 500 mg 1-0-1; change in antihypertensive drug regiment in elderly patients having vertigo in the morning: 0-0-X instead of X-0-0)\n\nExclusion Criteria:\n\n* Patients participating or having participated in an education program about their disease or treatment in the last 3 months, led by healthcare providers such as physicians, nurses, pharmacists or other (e.g. education provided by nurses for type I diabetes patients)\n\nPhysicians:\n\nInclusion criteria\n\n\\- Any physician treating a patient for one of the five long-term illnesses listed above is eligible to refer the patient to a pharmacy providing myCare start.\n\nPharmacies:\n\nInclusion criteria:\n\n* Have to be enrolled into the myCare Start service and comply to the requirements of the pharmacy quality system management of having access to a private consultation room or area\n* Must agree to participate in the research study, including the recruitment of control patients and the delivery of the myCare Start service to intervention patients.",{"count":162,"type":22},1600,[104],"In Phase B, the aim is to evaluate the myCare Start service in routine care within the ambulatory primary care medicine and community pharmacy setting in Switzerland. A Type II hybrid effectiveness-implementation study will be conducted to evaluate the effectiveness (improvement in adherence), cost-effectiveness and implementation of the service. This evaluation will allow us to build the necessary contextual relevant evidence base to support sustainable funding of the service in the long term.",[166,167,168,169,170,29,171],"Cardio-vascular Disease","Depression Disorders","Diabetes","COPD","Asthma Bronchiale","Medication Initiation for Long-term Conditions",[173,174,175,176,177,178,179,180,181,182,183],"patient adherence","medication adherence","medication initiation","long-term treatment","implementation science","interprofessional collaboration","outpatient care","community pharmacy","general practitioner","cost-effectiveness","medication adherence support programme","2025-06-16",{"date":145,"type":48},{"date":147,"type":22},{"date":188,"type":22},"2027-01",{"name":190,"class":92},"University of Geneva, Switzerland",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":56},"100594940","phase-2-effect-of-sinbiotic-with-multispecies-probiotics-on-liver-parameters-liver-enzymes-ultrasound-elastography-and-adipokines-in-same-cases-in-patients-with-metabolic-associated-steatotic-liver-disease-100594940","NCT07025980","Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease.","Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters in Patients With Metabolic Associated Steatotic Liver Disease","Inclusion Criteria:\n\n* MASLD confirmed by ultrasound and elastography with CAP \\> 260 dB\u002Fm\u002FMHz;\n* other causes of chronic liver disease excluded and\u002For diagnosis confirmed by liver biopsy,\n* presence of metabolic syndrome according to the definition of the International Diabetes Federation (IDF): waist circumference for women over 80 cm or over 94 cm for men, and at least two of the other criteria (treated hypertensive or blood pressure \\> 130\u002F85 mmHg determined during inclusion; treated diabetic or newly detected fasting serum glucose levels \\> 5.6 mmol\u002Fl; treated dyslipidemia or newly detected serum triglyceride levels \\> 1.7 mmol\u002FL or HDL \\\u003C 1.29 mmol\u002FL for women\u002F\\\u003C 1.03 mmol\u002FL for men),\n* signed informed consent.\n\nExclusion Criteria:\n\n* pregnancy,\n* significant alcohol intake (\\>30g\u002Fday in men, \\>20g\u002Fday in women),\n* presence of autoimmune, viral, cholestatic (primary biliary cholangitis, primary sclerosing cholangitis, obstructive biliary tree diseases) or metabolic (hemochromatosis, Wilson) causes of chronic liver disease, transplant patients, malignant diseases, free fluid in the abdomen, significant small bowel resections,\n* signs of liver cirrhosis or LSM\\>13 kPa measured TE,\n* use of medications that can promote the development of steatosis (e.g. corticosteroids, high doses of estrogen, methotrexate, amiodarone, valproate), and medications that can affect the composition of the microbiota for at least 3 months before the start of the study (antibiotics and probiotics),\n* inability to reliably measure CAP and LSM (IQR\u002Fmedian\\>30%),\n* severe psychiatric patients in whom cooperation and consent are questionable.",{"count":199,"type":22},114,[201],"PHASE2","Scientific hypothesis: the use of a synbiotic preparation with a multi-strain probiotic in patients with MASLD can lead to a decrease in non-invasive elastographic parameters of hepatic steatosis and fibrosis and an improvement in liver function.\n\nThe main objective of this study is to examine whether the test product affects the improvement of liver function measured by elastographic parameters or at least the prevention of further disease progression.\n\nThe goal of this clinical trial is to learn if sinbiotics works to improve liver function in adult patients with MASLD The main questions it aims to answer are:\n\nDoes sinbiotic lowers elastographic parameters od steatosis and fibrosis? Does it change liver function by lowering liver enzymes, blood lipids and sugar? Can sinbiotics lower CV risks and improve quality of life? Researchers will compare sinbiotic to a placebo (a look-alike substance that contains no drug) to see if sinbiotic works in MASLD patients.\n\nParticipants will:\n\nTake sinbiotic or a placebo every day (td) for 9 months Visit the clinic once every 3 months for checkups, and at the begining and after 9 months for blood tests and US with elastography Keep a diary of their symptoms, diet, activity",[204,107,108,29],"MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)",[206],"elastography; human LRG1, liver enzymes, metabolic- dysfuncion steatotic liver disease, metabolic syndrome; probiotics, treatment","2025-06-10",{"date":209,"type":48},"2025-06-18",{"date":211,"type":22},"2025-07-01",{"date":213,"type":22},"2029-07-31",{"name":215,"class":92},"Eva Cubric"]